The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and ...

Developed using advanced machine learning and leveraging Perthera’s extensive novel real world evidence pancreatic cancer data repository, PDACai analyzes patient genomic, clinical, epidemiological, ...

Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT) Initial Data Demonstrates ...

At ASCO 2025, several promising studies in pancreatic ductal adenocarcinoma (PDAC) were presented. In the neoadjuvant setting, the CASSANDRA trial compared the PAXG (nab-paclitaxel, capecitabine, ...

The results of the global phase 3 LAPIS trial suggest that the addition of pamrevlumab to standard chemotherapy fails to improve survival outcomes in patients with locally advanced pancreatic cancer ...

Researchers discovered that treating pancreatic cancer with a common chemotherapy drug makes immunotherapy more effective. Folinic acid elevates levels of two anti-cancer immune molecules within ...

Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other ...

- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT ®- - Ad-hoc analyses of pancreatic cancer ...

BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation More than 30% of patients with ...